Results 181 to 190 of about 32,586 (241)
Some of the next articles are maybe not open access.
Drugs of the Future, 2002
Fondaparinux (Org-31540 / SR-90107A) is a new drug chemically synthesized for treatment and prophylaxis of thromboembolic disease. Fondaparinux is a selective inhibitor of activated factor X. Its structure is the copy of the heparin pentasaccharide sequence, the shortest chain required for antithrombin inhibition of activated factor X without ...
Susan J, Keam, Karen L, Goa
+8 more sources
Fondaparinux (Org-31540 / SR-90107A) is a new drug chemically synthesized for treatment and prophylaxis of thromboembolic disease. Fondaparinux is a selective inhibitor of activated factor X. Its structure is the copy of the heparin pentasaccharide sequence, the shortest chain required for antithrombin inhibition of activated factor X without ...
Susan J, Keam, Karen L, Goa
+8 more sources
Programmable One-Pot Synthesis of Heparin Pentasaccharide Fondaparinux
Organic Letters, 2020 The clinically approved Fondaparinux (Arixtra) has been used for the treatment of deep vein thrombosis and acute pulmonary embolism since 2002 and is considered to be better than the low-molecular weight heparin in terms of anticoagulation response ...
Supriya Dey, Hong-Jay Lo
exaly +2 more sources
Organic Letters, 2023
Here, we disclosed a convenient procedure for the preparation of EPP [3,5-dimethyl-4-(2'-phenylethynylphenyl)phenyl] glycosides and their application to an effective synthesis of fondaparinux, the clinically approved anticoagulant heparin pentasaccharide.
Wei Liu, Zhifei Hu, Peng Xu, Biao Yu
semanticscholar +1 more source
Here, we disclosed a convenient procedure for the preparation of EPP [3,5-dimethyl-4-(2'-phenylethynylphenyl)phenyl] glycosides and their application to an effective synthesis of fondaparinux, the clinically approved anticoagulant heparin pentasaccharide.
Wei Liu, Zhifei Hu, Peng Xu, Biao Yu
semanticscholar +1 more source
Current Pharmaceutical Design, 2005
Fondaparinux is the first drug from the pentassaccharide factor X inhibitor class of anticoagulants to be approved for clinical use. It has been shown to be effective in the prevention of deep vein thrombosis in patients undergoing major orthopaedic surgery of the lower limbs. The drug is also being evaluated for use in the acute coronary syndromes and
Kiat T, Tan, Gregory Y H, Lip
openaire +2 more sources
Fondaparinux is the first drug from the pentassaccharide factor X inhibitor class of anticoagulants to be approved for clinical use. It has been shown to be effective in the prevention of deep vein thrombosis in patients undergoing major orthopaedic surgery of the lower limbs. The drug is also being evaluated for use in the acute coronary syndromes and
Kiat T, Tan, Gregory Y H, Lip
openaire +2 more sources
Fondaparinux Use in Patients With COVID-19: A Preliminary Multicenter Real-World Experience.
Journal of Cardiovascular Pharmacology, 2020The use of heparin has been shown to decrease the mortality in hospitalized patients with severe COVID-19. The aim of our study was to evaluate the clinical impact of venous thromboembolism prophylaxis with fondaparinux versus enoxaparin among 100 ...
V. Russo +12 more
semanticscholar +1 more source
Expert Review of Cardiovascular Therapy, 2009
Fondaparinux is a synthetic pentasaccharide belonging to a new group of anticoagulants that inhibit thrombin formation by inhibiting Factor Xa, which is located at the crossing of both the intrinsic and extrinsic pathways. It has a favorable pharmacokinetic profile, and its effect is predictable and the drug does not need platelet monitoring.
Sunil K, Nadar +4 more
openaire +2 more sources
Fondaparinux is a synthetic pentasaccharide belonging to a new group of anticoagulants that inhibit thrombin formation by inhibiting Factor Xa, which is located at the crossing of both the intrinsic and extrinsic pathways. It has a favorable pharmacokinetic profile, and its effect is predictable and the drug does not need platelet monitoring.
Sunil K, Nadar +4 more
openaire +2 more sources
Journal of clinical pharmacology, 2020
Hepatotoxicity with low‐molecular‐weight heparin (LMWH) or fondaparinux is a relatively common adverse reaction. This study assessed the effects of LMWH and fondaparinux on liver function in patients with pulmonary embolism based on a retrospective ...
Xu Yang +10 more
semanticscholar +1 more source
Hepatotoxicity with low‐molecular‐weight heparin (LMWH) or fondaparinux is a relatively common adverse reaction. This study assessed the effects of LMWH and fondaparinux on liver function in patients with pulmonary embolism based on a retrospective ...
Xu Yang +10 more
semanticscholar +1 more source
Pediatric Blood & Cancer, 2020
The incidence of venous thromboembolism (VTE) and use of anticoagulation are rising in children, but treatment options remain limited. As a newer anticoagulant, fondaparinux may be a safe and effective alternative with the benefit of once‐daily dosing ...
Xiaofan Shen, Rachel Wile, G. Young
semanticscholar +1 more source
The incidence of venous thromboembolism (VTE) and use of anticoagulation are rising in children, but treatment options remain limited. As a newer anticoagulant, fondaparinux may be a safe and effective alternative with the benefit of once‐daily dosing ...
Xiaofan Shen, Rachel Wile, G. Young
semanticscholar +1 more source